New Report Details 10 Molecular Testing Segments That Will Grow the Fastest in 2018
ROCKVILLE, Md., Dec. 20, 2017 /PRNewswire/ --Tests for hepatitis, nucleic acid blood testing and respiratory testing are among the fast-growing segments of molecular testing in 2018 and will exceed the average for revenue growth in molecular IVD, according to a new Kalorama Information report. Average molecular IVD products will see six percent growth, the areas identified will be higher, over the next five years. The finding was made in Kalorama Information's report Expected High-Growth Market Segments in Molecular Testing.
Molecular testing provides fast and accurate results and the presence of molecular tests has disrupted several testing markets over the past decade and a half, However, some segments have thrived and others are seeing mature growth levels. Kalorama Information report details the highest revenue growth areas of molecular testing, as considered by manufacturers of IVD instruments, reagents and supplies.
"Not all molecular testing is high revenue growth at the present time," said Bruce Carlson, Publisher of Kalorama Information. "We have analyzed various markets including infectious disease cancer and other testing and identified the best growth prospects."
Clinical molecular diagnostics refer to in vitro diagnostic (IVD) tests used in patient health care that detect, quantify or characterize nucleic acid analytes, whether pathogenic nucleic acid, patient DNA or patient RNA. As an IVD market, molecular diagnostics refer to the relevant test kits, other reagents and instruments that are used for clinical testing in settings that include reference laboratories, independent labs, hospital labs, other centralized clinical labs and near-patient testing sites such as clinics and physician offices. The primary technologies for clinical molecular diagnostics include nucleic acid amplification tests (NAATs) based on real-time PCR (qPCR) and other amplification-detection protocols; direct nucleic acid probe tests such as in situ hybridization (ISH) and its fluorescent ISH (FISH); next-generation sequencing (NGS); amplification followed by probe-based hybridization on arrays (or microarrays); and other related methods.
The report covers both high-growth product segments and regional markets of significance.
Kalorama Information's report reveals:
- High-Growth Areas in Molecular Infectious Disease Testing
- High-Growth Areas in Molecular Cancer Testing
- High-Growth Areas in Other Molecular Testing
- High-Growth Regions
- Overview of Molecular Test Technologies.
- Top Companies in High-Growth Molecular Testing Markets
- Conclusions and Projections to 2021
Clinical molecular diagnostics refer to in vitro diagnostic (IVD) tests used in patient health care that detect, quantify or characterize nucleic acid analytes, whether pathogenic nucleic acid, patient DNA or patient RNA. As an IVD market, molecular diagnostics refer to the relevant test kits, other reagents and instruments that are used for clinical testing in settings that include reference laboratories, independent labs, hospital labs, other centralized clinical labs and near-patient testing sites such as clinics and physician offices.
Kalorama Information's report can be found at: https://www.kaloramainformation.com/prod-toc/Expected-High-Growth-Segments-Molecular-Diagnostic-Testing-11329089/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.
Press Contact:
Bruce Carlson
212 807 2262
[email protected]
SOURCE Kalorama Information
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article